In vivo Pharmacology Studies

We are an efficient partner for in vivo pharmacology services with our experience in multiple therapeutic areas, target specific models, and a team of highly competent scientists.

In vivo pharmacology is essential to evaluate the complex physiological effects of a drug in the living organism. In vivo pharmacology studies are offered by APSL to assess the effectiveness and early toxicity of small compounds and large molecules. Our in vivo pharmacology services are backed by an AAALAC accredited vivarium.

Our expanding disease models include pain management, inflammation & auto immune diseases, metabolic disorders, oncology etc.

Speak to our experts

Few therapeutic areas where we offer pharmacology discovery services are highlighted below:

Pain Models & Measurements

APSL has successfully collaborated with the world’s top pharmaceutical companies for pain drug discovery. Our expertise and experience allow us to offer an extensive portfolio of services supporting drug discovery and development. We match the industry’s needs in the domains of:

Acute and chronic inflammatory pain
Visceral pain
Arthritic pain
Neuropathic pain

Type	Animal Model	Species/ strain	Validation standard
Acute Models	Acetic acid induced writhing	Male Swiss albino mice	Indomethacin/Tramadol
	Carrageenan-induced mechanical hyperalgesia	Male Wistar rat	Celecoxib
	Complete Freund’s adjuvant (CFA) induced thermal hyperalgesia	Male Sprague Dawley rat	Indomethacin
Arthritic Pain	CFA-induced mono arthritis pain	Male Sprague Dawley rat	Naproxen
Arthritic Pain	Monoidoacetate-induced osteoarthritis pai	Male Sprague Dawley rat	Diclofenac
Neuropathic Pain	Partial sciatic nerve ligation	Male Wistar rat	Gabapentin

Inflammation and Auto-immune Disorders

Our team of experts have developed in vivo models for autoimmune and inflammatory diseases. We offer inflammation animal models associated with:

Neurological diseases
Respiratory diseases
Arthritis
Skin diseases
Gastrointestinal diseases and

Type	Animal Model	Species/ strain	Validation standard
Acute Models	LPS-induced systemic inflammation (Plasma TNF-α)	Female wistar rat/ Male BALB/c mice	Roflumilast / Theophylline
	LPS-induced systemic inflammation (Plasma IL-17 )	Male C57BL/6 mice	Digoxin
	LPS-induced paw edema	Female wistar rat	Nimesulide
	Carrageenan-induced paw edema	Male wistar rat	Celecoxib
	Acute Arthus reaction	Female C57BL mice	Kinase inhibitor
	The SCF-induced systemic histamine release model	Female BALB/c mice	Anti C-KIT antibody
	Mouse passive cutaneous anaphylaxis model	Female C57BL/6 mice	Dexamethasone
	TNF + Zvad induced hypothermia	Female C57BL mice	Kinase inhibitor
Arthritis	Collagen-Induced Arthritis (Prophylactic)	Female Lewis rat	Leflunomide
	Collagen-Induced Arthritis (Therapeutic)	Female Lewis rat	Enbrel, Dexamethasone
	Adjuvant-Induced Arthritis (Prophylactic)	Female Lewis rat	Celecoxib
	Medial Meniscus Induced Tear Osteo Arthritic model	Female Lewis rat	Celecoxib
Dermatitis & Psoriasis	DNFB-induced contact dermatitis	Female CD1 mice	Leflunomide
	Oxazolone-induced contact dermatitis	Male SD rat	Dexamethasone
	Imiquimod-induced psoriasis model	Female Balb/c mice	Dexamethasone /Anti mouse IL-17 anti body
	IL-23-induced dermatitis model	Female Balb/c mice	Tofacitinib/
Colitis	Dextran Sulphate Sodium induced colitis	C57BL/6 mice	cyclosporin
Colitis	Trinitrobezene sulphonic acid-induced colitis	Female wistar rat/ BALB/c mice	Dexamethasone
Fibrosis	Unilateral ureteral obstruction model	Male C57BL/6 mice	Necrostatin-1
Acne	Hamster ear sebaceous gland model	Female Hamsters	spironolactone
Asthma	Ovalbumin/LPS induced neutrophilic asthma model	Male C57BL/6 mice	Digoxin
MS	MOG-induced EAE model in C57BL/6	Female C57BL/6 mice	Copaxone

Metabolic Disorders (Diabetes, Obesity and Atherosclerosis)

The team has vast experience in conducting customized metabolic disorder animal models.

Type	Strain-Species	Activity/test Model	Validating/Standards
MD (Diabetes and Obesity)	Mice and rats	OGTT, IPGTT, IVLTT, and Euglycemic clamp study	Pioglitazone/Exenatide
	Swiss albino mice / Wistar rats/CD1 mice	Acute food intake modulating activity	Rimonabant/ PYY 3-36/Liraglutide
	CD1 mice	3 days of administration of food intake and body weight lowering activity	PYY 3-36
	db/db mice	Blood glucose lowering and anti-dyslipidemic activity	Pioglitazone/ liraglutide
	Zucker fa/fa rats	Anti-dyslipidemic activity and insulin-sensitizing activity	Fenofibrate/Pioglitazone
	ob/ob mice	Body weight lowering and insulin-sensitizing activity	Metformin/Pioglitazone
	C57BL/6 - DIO mice	Body weight lowering activity	Rimonabant/PYY 3-36
CV (Atherosclerosis)	LDLr -/-Mic	Anti-atherosclerotic activity	Fenofibrate
	Swiss albino mice	Lipid-lowering activity	Fenofibrate
	High-fat-fed Sprague Dawley rats	Acute lipid (TC, TG) lowering activity	Fenofibrate
	Golden Syrian Hamster	HDL elevating activity	Torcetrapib

Oncology Animal Model

APSL has significant experience in oncology drug discovery. We offer a large collection of tumor models for small & large molecule drug discovery.

Cancer type	Cell line	Mice	Model type
Lung cancer, NSCLC	A549, Known to be KRAS mutant and EGFR wild type	Ncr nude mice	Xenograft, subcutaneous
Multiple Myeloma	H929	NOD SCID mice	Xenograft, subcutaneous
Breast cancer	MCF-7 cells are ER+, progesterone receptor-positive, and HER2 negative.	Ncr nude mice	Xenograft, subcutaneous
Prostate cancer	22RV1, cell line has been derived from a human prostatic carcinoma xenograft, CWR22R	Ncr nude mice	Xenograft, subcutaneous
Colon cancer	COLO 205 non metastatic	Ncr nude mice	Xenograft, subcutaneous
Leukemia	MV-4-11, human biphenotypic B myelomonocytic leukemia	Ncr nude mice	Xenograft, subcutaneous
Colon cancer	CT26	BALB/c mice	Syngeneic, subcutaneous Established model
Ovarian cancer	SKOV-03	Ncr nude mice	Xenograft, subcutaneous Established model
Acute myeloid leukemia	MOLM-13	NOD SCID mice	Xenograft, subcutaneous Established model

Miscellaneous models

Mouse/ rat whole blood and splenocyte assays with different stimulants (LPS, NECA) and evaluation of cytokines and biomarkers using flow cytometer.
Oxidative stress markers evaluation in rats administered with repeat intravenous Iron formulation.
Evaluation of test compounds potential in modulating serum Iron and hepcidin expression modulation in restricted iron diet fed rats.
Evaluation of test compounds potential in muscle regeneration in thermal injury mice model.
Anti-acne potential evaluation of test compounds in hamsters ear sebaceous gland model.
Evaluation of test compounds efficacy in mice post-operative ileus model.
Evaluation of test compounds efficacy in gastric emptying and intestinal motility in mice model

Why Aurigene In vivo Pharmacology Studies Services?

Experience in submissions to the US FDA and DCGI

Highly qualified and experienced scientists

Capacity to handle more than 600 rodents at a given time

AAALAC accredited vivarium

Other Services

DMPK

GLP and Non-GLP Toxicology Studies

In vitro Biology

Pharmaceutical Microbiology Testing

Virtual Tour

Hyderabad R and D Center

Bangalore R and D Center

Pharmaceutical Analytical Services

Polymorph Screening

ADME/DMPK Services

Drug Formulation Services

In vivo Pharmacology

Medicinal Chemistry

Microbiology Testing

Peptide Synthesis

Development & Kilo Lab

Toxicology Studies

Connect with our scientific experts for your drug discovery, development, and manufacturing needs

We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.

Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.

Country

Page name

page url

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

I agree to receive updates from Aurigene

* I agree and accept the Privacy Policy and Terms of Use of this website.

Resources

OCTOBER 01, 2024

PROTACs: Research for a life without cancer

PROTACs: Proteolysis-targeting chimeras (PROTACs) are a rapidly evolving field with promising applications in cancer, neurodegenerative diseases, and other conditions where the regulation of protein levels is crucial. PROTACs are a novel class of small molecules designed to target specific proteins for degradation by the ubiquitin-proteasome sys...

SEPTEMBER 24, 2024

Good practices in non-clinical toxicology assessment to accelerate IND and NDA Submissions
Read More
AUGUST 30, 2024

Continuous Flow Chemistry: A Game-Changer for Pharmaceutical Production
Read More
JULY 17, 2024

mRNA Technology and the Brief History of New Vaccine
Read More

View All

Advancement in personalized medicine and how the CRDMO industry is part of the solution

Personalized medicine is transforming the healthcare landscape by customizing treatment plans to individual patients’ unique genetic, clinical and environmental characteristics. These are effective and less invasive treatments for a wide range of conditions. Contract Research, Development and Manufacturing Organizations (CRDMOs) play an important role...

View All

Cell Line Development

We enable development of stable and high yielding recombinant Mammalian and Microbial lines. ...

View All

Case study: Tackling CYP 2C9 inhibition challenges

The Problem: Active compounds in a project were found to be highly potent inhibitors of CYP 2C9 The compounds selectively inhibited CYP 2C9 with IC50 values <100 nM There was no considerable inhibition of the other CYP isoforms Our Mitigation Approach: CYP 2C9 inhibition data was generated for a larger set of co...

View All

Synthesis of Anti-covid Drug Nirmatrelvir Using Flow Chemistry

2022

Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...

Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.

2005

Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More
Wang-OSO3H catalyzed green synthesis of bioactive isoindolo[2,1- a ]quinazoline-5,11–dione derivatives: An unexpected observation

2005

The sulphonic acid-functionalized Wang resin (Wang-OSO3H) was explored as a polymeric and recov- erable acidic catalyst for the synthesis of isoindolo[2,1- a ]quinazoline-5,11–dione derivatives under green conditions. Thus the Wang-OSO3H ...
Read More
Polycyclic Aromatic Compounds: A Simple and Efficient [(n-Bu3Sn)2MO4]n Catalyzed Synthesis of Quinazolinones and Dihydroquinazolinones

2005

A novel unprecedented approach for the synthesis of various quinazolinones and dihydroquinazolinones has been using [(n-Bu3Sn)2MO4]n as a catalyst. The reaction has been screened ...
Read More

View All

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

Proceed Back

In vivo Pharmacology Studies